Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Mayo Clinic, Rochester, Minnesota